On July 11th, the WHI Clinical Coordinating Center launched a
new public site.
participants, and the
general public are encouraged to check out our newly designed site as a starting point for learning about the study.
Users wishing to directly access this website should remember or bookmark the address
https://sp.whi.org. In addition, a link to this site can be found in the footer of our new public site, labeled as "WHI SharePoint."
We hope you enjoy the new website. Please direct any questions or concerns you might have to the
WHI Help Desk.
Carolyn J. Crandall, MD, MS, FACP, Professor of Medicine at the David Geffen School of Medicine at University of California, Los Angeles received the best paper of the year award from the journal Menopause. The award was announced at the North American Menopause Society Annual Meeting in September 2019.
The paper found that after menopause, up to half of women will experience symptoms of atrophic vaginitis. The symptoms of atrophic vaginitis include vaginal dryness, burning, and irritation, including pain with intercourse. These symptoms have negative effects on women's lives. There are many available preparations of vaginal estrogen therapies available to treat the symptoms of atrophic vaginitis. In this study, we examined data from 45,663 women in the WHI Observational Study to compare the occurrence of several important health outcomes among women using, versus women not using, vaginal estrogen therapy. We found that the risks of cardiovascular disease and cancer were not elevated among postmenopausal women using vaginal estrogen. These results are reassuring regarding the safety of these preparations.
Crandall CJ, Hovey KM, Andrews CA, Chlebowski RT, Stefanick ML, Lane DS, Shifren J, Chen C, Kaunitz AM, Cauley JA, Manson JE. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the WHI Observational Study. Menopause. 2018 Jan;25(1):11-20. doi: 10.1097/GME.0000000000000956. Epub 2017 Aug 14.
View past news stories